EMMA News and Press, Emmaus Life Sciences Incorporation From 12/23/19

TORRANCE, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, today reported that it expects to receive shortly the initial purchase orders relating to taiba Healthcare’s early access program for Endari®...

Gainers:  LMP Automotive (NASDAQ: LMPX ) +95% . More news on: LMP Automotive Holdings, Inc., Sarepta Therapeutics, Inc., Cohen & Company Inc., Stocks on the move, Read more ...

Emmaus Life Sciences ( OTC:EMMA ): Q3 GAAP EPS of -$0.60. Revenue of $6.08M (+24.6% Y/Y) Press Release More news on: Emmaus Life Sciences, Inc., Earnings news and commentary, Healthcare stocks news, ,

-- Net Revenues Increased 25% Year-Over-Year, Company Opens and Expands Class of Trade with Community Hematologists and Correctional Facilities -- TORRANCE, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment,...

Company Enters Into Common Stock Purchase Agreement with Vivozon, Inc. TORRANCE, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, today reported that Vivozon, Inc. has executed a stock purchase agreement for...

TORRANCE, Calif., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease (SCD) treatment, today reported preliminary gross sales results of $7.0 million for the third quarter ended September 30, 2019 compared to $6.2 million for the sec...

TORRANCE, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today the allowance by the Indian Patent Office of its patent application (serial number 1255/KOLNP/2014) for methods and compositions of pharma...

Emmaus Life Sciences ( OTC:EMMA +2.5% ) common stock trades on the OTCQB marketplace, effective September 26, 2019. More news on: Emmaus Life Sciences, Inc., Read more ...

TORRANCE, Calif. , Sept. 26, 2019 /PRNewswire/ --  Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, today announced it is approved to have its common stock trade on the OTCQB marketplace, effective September 26, 2019 . The common stock of Em...

Gainers:  Emmaus Life Sciences ( OTC:EMMA ) +64% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +23% . SYNNEX Corporation (NYSE: SNX ) +20% . Contango Oil & Gas Company (NYSEMKT: MCF ) +17% . R.R. Donnelley & Sons Company (NYSE: RRD ) +16% . Comtech Telecommunications (NASDAQ...